Growth Inhibition of Kappa-Selenocarrageenan Combined with Paclitaxel on Human Breast Carcinoma MCF-7 Cells

Abstract:

To investigate the combined effect of kappa-selenocarrageenan (KSC) and paclitaxol (Taxol) on MCF-7 cells in vitro. The cytotoxic effect of both drugs on MCF-7 cells was measured by MTT assay, and the King’s principle was used to evaluate the interaction of drugs combination. KSC and Taxol alone have significant growth inhibitory effects on HepG-2 cells in dose- and time-dependent manners, and the combination groups show more remarkable anti-proliferative activities than the two drugs alone. The IC₅₀ values of KSC and Taxol alone on HepG-2 cells for 72h are 48.445 mg/L and 2.592 nmol/L, respectively. While combining with 30 mg/L KSC, IC₅₀ value of Taxol decreases sharply to 0.353 nmol/L. Q values of their combination are 0.908~1.051, which demonstrates additive effect. In short, selenium polysaccharide has striking inhibition effect on MCF-7 cells and can enhance efficacy of chemotherapeutic agents and reduce their side effects.

• Periodical: Advanced Materials Research (Volumes 343-344)
• Pages: 535-537
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.343-344.535
• Online since: September 2011
• Authors: Na Ling, Chun Ying Chen, Yan Yan Xu, Yu Bin Ji
• Keywords: Combination, Growth Inhibition, Kappa-Selenocarrageenan, MCF-7 Cells, Paclitaxel

References

[1] P. B. Schiff, J. Fant, and S. B. Horwitz, Promotion of microtubule assembly in vitro by Taxol, Nature, vol. 277, no. 5698, pp.665-667, February (1979).

DOI: 10.1038/277665a0

[2] A. U. Buzdar, F. A. Holmes, and G. N, Hortobagyi, Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience, Semin. Oncol., vol. 22, pp.101-104, June (1995).

[3] W. P. McGuire, E. K. Rowinsky, N. B. Rosenshein, F. C. Grumbine, D. S. Ettinger, et al, Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms, Ann. Intern. Med., vol. 111, pp.273-279, August (1989).

DOI: 10.7326/0003-4819-111-4-273

[4] F. A. Holmes, R. S. Walters, R. L. Theriaut, A. D. Forman, L. K. Newton, M. N. Raber, et al, Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer, J. Natl. Cancer Inst., vol. 83, pp.1797-1805, December (1991).

DOI: 10.1093/jnci/83.24.1797-a

[5] R. C. Donehower, E. K. Rowinsky, L. B. Grochow, S. M. Longnecker, and D. S. Ettinger, Phase I trial of taxol in patients with advanced cancer, Cancer Treat. Rep., vol. 71, pp.1171-1177, December (1987).

[6] L. C. Clark, G. F. Combs, B. W. Turnbull, E. H. Slate, D. K. Chalker, et al, Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial, J. Am. Med. Assoc., vol. 276, pp.1957-1963, December (1996).

DOI: 10.1001/jama.1996.03540240035027

[7] S. Y. Yu, Y. J. Zhu, W. G. Li, Q. S. Huang, C. Z. Huang, C Hou, A preliminary report on the intervention trials of primary liver cancer in high-risk populations with nutritional supplementation of selenium in China, Biol. Trac. Elem. Res., vol. 29, pp.289-294, June (1991).

DOI: 10.1007/bf03032685

[8] Z. J. Lin, and Y. Wang, Kappa-selenocarrageenan -A new type of organic selenium compounds, in Trace element analysis and application, Wuhan: Tongji Medical University Publisher, 1993, pp.34-36.

[9] Z. W. Zhang, H. L. Wei, H. X. Su, Immunomodulatory and anti-tumor activities of kappa-selenocarrageenan, Lanzhou Daxue Xue Bao, vol. 31, no. 2, pp.88-91, June (2005).

[10] N. Ling, D. Deng, Y. B. Ji, Effect of Combination of Kappa-selenocarrageenan and Paclitaxel on Human Hepatoma HepG-2 Strain, Asia-Pacific Traditional Med, vol. 5, no. 11, pp.13-15, November (2009).

[11] Z. J. Jin, Addition in drug combination, Acta Pharmacol. Sin., vol. 1, pp.70-76, December (1980).